Clinical trial

ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

Recruiting now · Not applicable · 1 countries · Registry ID NCT06174389

Recruiting nowNot applicableInterventional

What this study is about

Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 60 Years
SexAll
Healthy volunteersAccepted
ConditionObesity

Full registry criteria

Inclusion Criteria: * BMI 30.0 - 50.0 kg/m2 * Able to attend study intervention classes and study visits/assessments * Independently living with access to food preparation facilities Exclusion Criteria: * Current smoker or regular use of nicotine containing products and/or cannabis * Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use * Known cognitive impairments or h/o stroke * Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%)) * Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate * Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding * Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants * History of bariatric surgery * History of eating disorder * Current participation in a formal weight loss program * Prior or current participation in a research study involving weight loss * Weight-reduced by \>10% within past year * Weight \> 330 pounds (MRI limit) * Allergy or intolerance to or unwillingness to consume study foods provided at visit * MRI contraindication (e.g., implanted metal, claustrophobia) * Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures * Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

Treatments and study arms

Behavioral Weight Loss Program

Behavioral

Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.

Primary outcomes

Change in maximal respiratory capacity (oxygen consumption rate) in peripheral blood mononuclear cellsFrom baseline to active weight loss (at least 21 days of weight loss equivalent or greater than 0.5 pounds per week) and from baseline to weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).

Mitochondrial maximal respiratory capacity will be measured in fasting samples from peripheral blood mononuclear cells.

Change in fMRI BOLD signalFrom baseline to a weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).

fMRI BOLD signal to visual food cues within a priori brain regions of interest pre and post consuming a standardized meal. Meal-induced change will be calculated by post-pre meal BOLD signal.

Entry into involuntary weight loss plateauthroughout 18-month enrollment

binary outcome (Y/N) and time from baseline

Study locations

2 locations were listed when this page was built. The first 40 are shown.

Fred Hutch Cancer Center🇺🇸 Seattle, Washington, United States
Diana LowryContact
University of Washington - South Lake Union🇺🇸 Seattle, Washington, United States
Mary WebbContact